Oligonucleotide Complex Compositions And Methods Of Use As Gene Alteration Tools
AssigneeThe General Hospital Corporation
InventorsDavid R. Tabatadze, Paul C. Zamecnik, Malay K. Raychowdhury, Horacio F. Cantiello
Life of this patent
Estimating the term…
Abstract
Compositions and methods of treatments of cells are provided for altering the phenotype of a cell by administering an oligonucleotide complex to the cell, the complex having two strands and chemical modifications.
Claims25
A method for targeted gene repair, comprising
- contacting a non-repaired target RNA with a phosphorothioate (PS) containing sequence comprising a deoxynucleotide with RNase H resistant flanking ends;
- contacting the non-repaired target RNA with an RNA oligonucleotide complex comprising a first oligonucleotide and a second oligonucleotide,
- said first oligonucleotide comprising a sequence complementary to a repaired target RNA, wherein the RNA sequence of the first oligonucleotide comprises an RNase H-resistant modification, and wherein the RNase H-resistant modification is the addition of a 2-O-methyl moiety, and
- said second oligonucleotide comprises an RNA sequence complementary to at least 6 nucleotides of the first oligonucleotide at the site in the sequence of the first oligonucleotide which is not complementary to the non-repaired target RNA;
- and
- hybridizing said complex to said non-repaired target RNA in the presence of an RNase, wherein a repaired RNA is produced.
5-6. (canceled)
A method for treating or ameliorating a symptom of cystic fibrosis in a subject in need thereof, comprising
- administering a phosphorothioate (PS) containing sequence comprising a deoxynucleotide with RNase H resistant flanking ends,
- administering an RNA oligonucleotide complex directed to a non-repaired target RNA, said complex comprising a first oligonucleotide and a second oligonucleotide,
- said first oligonucleotide comprising a sequence complementary to a repaired target RNA, wherein the RNA sequence of the first oligonucleotide comprises an RNase H-resistant modification, and wherein the RNase H-resistant modification is the addition of a 2-O-methyl moiety, and
- said second oligonucleotide comprises an RNA sequence complementary to at least 6 nucleotides of the first oligonucleotide at the site on the sequence of the first oligonucleotide which is not complementary to the non-repaired target RNA;
- and
- wherein administration produces a repaired targeted RNA, thereby treating or ameliorating symptom of cystic fibrosis.
19-20. (canceled)
An RNA oligonucleotide complex for modulating the expression or activity of a cystic fibrosis transmembrane conductance regulator (CFTR) gene product, the complex comprising a first oligonucleotide and a second oligonucleotide, said said first oligonucleotide comprising a sequence complementary to a repaired target RNA, wherein the RNA sequence of the first oligonucleotide comprises an RNase H-resistant modification, and wherein the RNase H-resistant modification is the addition of a 2-O-methyl moiety, and said second oligonucleotide comprises an RNA sequence complementary to at least 6 nucleotides of the first oligonucleotide at the site in the sequence of the first oligonucleotide which is not complementary to the non-repaired target RNA, wherein said first and second oligonucleotide are annealed.
27-40. (canceled)
Dependencies are inferred from the claim text.